Ichnos Sciences signs licensing pact with Astria Therapeutics for OX40 antagonist monoclonal…
Astria Therapeutics is granted global rights to develop and commercialise OX40 portfolio, comprised of Telazorlimab and its…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
inflammatory diseases
Eli Lilly enters into $960 million deal with Rigel Pharma to develop autoimmune therapy
Under the deal, Lilly will foot the costs of global commercialisation for the therapy, R552, and Rigel will have the right to…